References
- Parmiani G., Radrizzani M. Autologous cellular immune response in cancer today. The Cancer Journal 1991; 4: 10–13
- Coulie P. G., Somville M., Lehmann F., et al. Precursor frequency analysis of human cytotoxic T lymphocytes directed against autologous melanoina cells. Int J Cancer 1992; 50: 289–297
- Finke J. H., Rayman P., Edinger M., et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+T-cell line. J. Immunother 1992; 11: 1–11
- Itoh K., Salmeron M. A., Morita T., et al. Distribution of autologous tumor specific cytotoxic T-lympho-cytes in huinan metastatic melanoma. Int J Cancer 1992; 52: 52–50
- Weber J. S., Yang T. C., Topalian S. L., et al. The use of IL-2 and LAK cells for the treatment of patients with non-Hodgkin's lymphomas. J Clinical Oncology 1992; 10: 33–40
- Schuler M., Huber C., Peschel C. Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. Ann Hematol 1995; 71: 57–63
- Harris N. L., Jaffe E. S., Stein H., et al. A revised European American Classification of lymphoid neoplasms: A proposal from the International lymphoma study group. Blood 1991; 84: 1361–1392
- Whiteside T. L., Miescher S., Macdonald R., von Fliedner V. Separation of tumor infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986; 90: 221–23
- Shimizu Y., Weidmann E., Iwatsubi S., et al. Characterization of human autotumor-reactive T-cell clones obtained from tumor infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res 1941; 5: 6153–6162
- Nadlarni J. J., Mehta B. A., Koppikar S. B., et al. Natural killer activity and NK cytotoxic factors in preipheral blood and lymph node of Non-Hodgkin's lymphoma patients. Neoplasma 1981; 36: 701–708
- Nadkarni J. J., Jhaver K. G., De A. K., et al. Characterization of lymphokine-activated killer cells from peripheral blood & lymph nodes of Non-Hodgkin's lymphoma patients. Neoplasma 1993; 40: 15–10
- Mehta B. A., Satam M. N., Advani S. H., Nadkarni J. J. In vitro modulation of NK cell activity in NHI, patients after therapy. Cancer Immunol Immunother 1989; 28: 148–152
- Kudoh S., Wang Q., Hidalgo O. F., et al. Responses to T-cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T-cells from B-cell non-Hodgkin's lymphomas. Cancer Immunol Immunother 1995; 40: 175–184
- Garciam C. F., Lowder J., Mecker T. C., et al. Differences in “host infiltrates” among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. J Immunol. 1985; 135: 4252–4260
- Yssel H., Spits H., de Vries J. E. A cloned human T-cell line cytotoxic for autologous and allogeneic B-lymphoma cells. J Exp Med 1981; 160: 239–254
- Luna-Fineman S., Lee H. E., Wesley P. K., et al. Human cytotoxic T lymphocytes specific for autologous follicular lymphoma recognise immunoglobulin in a major histo-compatibility complex restricted fashion. Cancer 1992; 70: 2181–2186
- Shi I., Bonnefoix T., Vacon F. H. L., et al. Autotumor reactive T-cell clones among tumor infiltrating T-lymphocytes in B-cell non-Hodgkin's lymphoma. Br., J Immunol 1995; 90: 837–843
- Jerome K. R., Barnd D. L., Bendt K. M., et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognise an epitope present on the protein core of a mucin molecule preferentially expressed by the malignant cells. Cancer Res. 1991; 51: 2908–2916
- Avila-Carino J., Torsteindottir S., Bejarano M. T., et al. Combined treatment with IFNγ and TNFα upregulates the expression of HLA class I determinants in Burkitt lymphoma lines. Cell Immunol. 1988; 117: 303–311
- Vanky F., Wang P., Patarroyo M., Klein E. Expreision of adhesion inolecule ICAM-I and major histo-compatibility complex class I antigens on human tumor cells is required for the interaction autolognus lymphocytes in vitro. Cancer Immunol Immunother 1990; 31: 19–27
- Vanky F., Hising C., Sjowall K., et al. Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon γ and tumor necrosis factor a treatment of tumor cells potentiates their interaction with autologous blood lymphocytes. Cancer Immunol Innnunother. 1995; 41: 217–276